Your first 90 days
Your first 90 days on Hemlibra for hemophilia A
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Hemlibra replaces regular factor VIII or bypassing agent prophylaxis with a shot under the skin, given by you or a caregiver at home after training. The first month is a run of 4 weekly loading doses. After that comes the schedule you and the hematologist choose, along with a new plan for treating any breakthrough bleed. This page lays out that stretch from the FDA label, Genentech's HEMLIBRA Access Solutions and one insurer's written rules.
What has to happen before the first bottle ships
Hemlibra has no REMS, so the first dose waits on an insurance approval, a specialty pharmacy delivery and injection training at the hemophilia clinic. These are the 6 things in the way, in order.
A plan for your current prophylaxis
The label says prophylactic bypassing agents stop the day before the first Hemlibra dose.
- Prophylactic factor VIII may continue during the first week of Hemlibra.
- The hematologist sets the exact plan with you before day 1.FDA label
A plan for breakthrough bleeds
The Medication Guide asks you to follow your hematologist's instructions on when to use an on-demand bypassing agent or factor VIII.
- It also covers the dose and schedule for a bleed.
- Write this plan down and keep it with your supplies.FDA label
Injection training
The label says a patient or caregiver may inject Hemlibra after proper training, if a healthcare provider decides it is appropriate.
- Self-injection is not recommended for children under 7, so a caregiver gives those doses.
- Only a caregiver or healthcare provider should inject into the upper outer arm.FDA label
Your weight, for the dose
Every Hemlibra dose is set in milligrams per kilogram of body weight.
- The Medication Guide asks you to tell your healthcare provider when your weight changes.
- This matters most for babies and growing children.FDA label
Enrollment and the insurance approval
HEMLIBRA Access Solutions needs 2 forms, a Prescriber Service Form from the office and a Patient Consent Form from you.
- A Case Manager then checks your coverage, any prior authorization and which specialty pharmacy your plan wants.HEMLIBRA Access Solutions
A specialty pharmacy delivery
Hemlibra is dispensed through specialty pharmacies, treatment center pharmacies and hospital pharmacies.
- Genentech says more than 100 specialty pharmacies carry it.
- You also need a syringe, a transfer needle with a filter and an injection needle, which may look different depending on your pharmacy.HEMLIBRA Access Solutions
The days that matter
Counted from the first dose, with the 4 weekly loading doses, the switch at week 5, and later doses on each maintenance schedule. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Forms, then the benefits check
The office sends the Prescriber Service Form, and you sign the Patient Consent Form online or on paper.
- Genentech says help begins once both arrive.
- No source sets how long insurance approval takes.
Delivery and training
The specialty pharmacy ships the vials, which go in the fridge, and the injection supplies.
- The hemophilia clinic shows you or your caregiver how to prepare and inject a dose before the first one.
Bypassing agent prophylaxis stops
For people with inhibitors, the label says prophylactic bypassing agents stop the day before the first Hemlibra dose.
- Ask the hematologist which agent to keep on hand for a breakthrough bleed.
Loading dose 1
Three milligrams per kilogram, injected under the skin of the belly, thigh or upper outer arm.
- Prophylactic factor VIII may continue during this first week, according to the label.
Loading dose 2
Same dose, a week later, at a different spot on the body from the last shot.
- Skin reactions where the needle went in were the most common side effect in the trials, in 22%.
Loading dose 3
Headache and joint pain each occurred in 15% of trial patients.
- Call your doctor for medical advice about side effects that bother you.
Loading dose 4, the last weekly loading dose
This dose finishes the loading phase.
- Each carton holds one vial, and the maintenance dose differs, so check that the next order arrives in time.
First maintenance dose, week 5
Genentech says the maintenance dose starts at week 5.
- The label's options are 1.5mg/kg every week, 3mg/kg every 2 weeks or 6mg/kg every 4 weeks.
Second maintenance dose, if every 2 weeks
On the every-2-week schedule, doses fall on days 29, 43, 57, 71 and 85.
- In the HAVEN 3 trial, 60% on this schedule had no treated bleeds.
Second maintenance dose, if every 4 weeks
On the every-4-week schedule, doses fall on days 29, 57 and 85.
- In HAVEN 4, 52.8% of people without inhibitors on this schedule had no treated bleeds.
Three months in
On every schedule a dose falls on day 85.
- More breakthrough bleeds than usual can be a sign of antibodies against Hemlibra, which the label says to report promptly.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Hemlibra label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated July 11, 2025, read from the FDA's label database today. FDA label
- July 2025
The FDA approved adding hypersensitivity to the list of side effects reported since approval, on July 8th.FDA letter
- January 2024
A new 12mg vial was added to support use in newborns and reduce wasted medicine. The immunogenicity sections were also updated.FDA letter
- June 2022
Rash, hives and angioedema were added as side effects reported since approval.FDA letter
- December 2021
The warnings, side effects, counseling and Medication Guide were updated with new data on antibodies against Hemlibra.FDA letter
- September 2021
At the FDA's request, the label added that Hemlibra was not studied in severe liver or kidney disease. It also added that the aPCC interaction may last up to 6 months after the last dose.FDA letter
- October 2018
The FDA widened approval to people with hemophilia A without factor VIII inhibitors, from newborns up. It also added the 6mg/kg every-4-week maintenance dose.FDA letter
- November 2017
The FDA first approved Hemlibra on November 16th for hemophilia A with factor VIII inhibitors.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- The loading dose, then a maintenance dose
The label gives 3mg/kg once a week for the first 4 weeks.
- After that the maintenance dose is 1.5mg/kg every week, 3mg/kg every 2 weeks or 6mg/kg every 4 weeks.
- The label says the choice can weigh which schedule makes doses easier to keep.FDA label
- If a dose is missed
The label says to give a missed dose as soon as possible and then return to the usual schedule.
- Never give 2 doses on the same day to make up for a missed one.FDA label
- Where the shot goes
Use the belly, the thighs or the upper outer arms, with a different spot each time.
- Avoid moles, scars, and skin that is tender, bruised, red, hard or broken.
- Only a caregiver or healthcare provider should use the upper outer arm.FDA label
- Who gives the shot
A patient may self-inject, or a caregiver may give the dose, after training and with a healthcare provider's approval.
- The label does not recommend self-injection for children under 7.FDA label
- Treating a breakthrough bleed with aPCC (FEIBA)
The boxed warning describes thrombotic microangiopathy and blood clots when aPCC averaged more than 100 units per kilogram a day for 24 hours or more.
- If you think you need more than 100 units per kilogram of aPCC in total, talk to your hematologist first.FDA label
- Clotting lab tests read wrong
Hemlibra makes the aPTT test and any test built on it read falsely, including one-stage factor VIII tests and clotting-based inhibitor tests.
- This effect can last up to 6 months after the last dose.
- Tell every doctor and lab before any blood test or procedure.FDA label
- Storage
Keep vials in the fridge at 36°F to 46°F (2°C to 8°C), in the carton, never frozen or shaken.
- Unopened vials can be out of the fridge for a total of 7 days, below 86°F (30°C).
- Once drawn into a syringe, use the dose right away.Supplies and storage
- Pregnancy, breastfeeding and birth control
There are no data on Hemlibra in pregnancy, and it is not known whether it passes into breast milk.
- The label says females who can become pregnant should use birth control during treatment.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Signs of thrombotic microangiopathy
Confusion, weakness, swelling of the arms and legs, yellow skin or eyes, belly or back pain, nausea or vomiting, feeling sick, or passing less urine.
- The Medication Guide says to get medical help right away.FDA label
Signs of a blood clot
Swelling, pain or redness in an arm or leg, shortness of breath, chest pain or tightness, a fast heart rate, or coughing up blood.
- Also watch for feeling faint, headache, a numb face, eye pain or swelling, or trouble seeing.
- Get medical help right away.FDA label
More bleeds than usual
In trials, 5.1% made antibodies against Hemlibra, and in uncommon cases, under 1%, these stopped it working.
- Contact your healthcare provider right away if bleeds increase.FDA label
Common side effects
In the trials, skin reactions where the shot went in occurred in 22%, headache in 15% and joint pain in 15%.
- Fever and diarrhea each occurred in 6%.
- All skin reactions were mild to moderate, and 93% went away without treatment.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedThe Cigna policy below wants a documented hemophilia A diagnosis, routine prophylaxis use and a hemophilia specialist. A Field Reimbursement Manager or Case Manager can share appeal resources, but HEMLIBRA Access Solutions cannot complete or submit an appeal.Cigna policy
- The plan wants prophylaxis agents stoppedCigna asks the hematologist to confirm that prophylactic bypassing agents will stop. For people without inhibitors, prophylactic factor VIII must stop within 4 weeks of the first dose. Agents used to treat a breakthrough bleed are still allowed.Cigna policy
- You are on immune tolerance inductionFor people with inhibitors, Cigna's policy covers Hemlibra only for patients who are not undergoing immune tolerance induction. The hematologist decides the order of treatments.Cigna policy
- You also take another non-factor drugCigna does not cover Hemlibra used together with Alhemo, Hympavzi or Qfitlia. The request needs to show a single non-factor prophylaxis drug.Cigna policy
- The prescription went to the wrong pharmacyHemlibra is dispensed through specialty, treatment center and hospital pharmacies. A Case Manager can tell the office which specialty pharmacy your plan requires, and the office resends it there.HEMLIBRA Access Solutions
- A copay you cannot payWith commercial insurance, the copay program may bring the cost to as little as $0, with up to $15,000 a year in help. Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, VA and DoD plans are excluded. Independent foundations may help people with commercial or public insurance, including Medicare and Medicaid.Financial assistance
- No insurance, or no coverage for HemlibraThe Genentech Patient Foundation gives Hemlibra free to people who qualify. Uninsured patients, or insured patients without Hemlibra coverage, need incomes under $150,000.Financial assistance
Cigna prior authorization policy, September 1, 2026
- Used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
- A documented diagnosis of hemophilia A, with or without factor VIII inhibitors
- With inhibitors: the prescriber says prophylactic bypassing agents will be stopped, and the patient is not on immune tolerance induction
- Without inhibitors: the prescriber says prophylactic factor VIII will stop no later than 4 weeks after the first Hemlibra dose
- Prescribed by, or in consultation with, a hemophilia specialist
- Dosed as the label says, with 4 weekly loading doses of 3mg/kg and one of the 3 maintenance schedules
- Not used together with Alhemo, Hympavzi or Qfitlia
Approval length. A year at a time; renewal asks for a beneficial response, such as fewer or less severe bleeds.
This policy took effect on September 1, 2026 and cites the July 2025 Hemlibra label, which is still current. Its September 2026 update dropped an earlier requirement for an inhibitor test within the past 30 days. Treating a breakthrough bleed with factor VIII or a bypassing agent is allowed under it. For people without inhibitors, its text still lists no past factor VIII use as a condition. Its change log describes removing a related rule, so the office may need to confirm this with Cigna. It is here as an example of what a plan asks for, not as a rule. Cigna policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- A Case Manager who explains your coverage, finds financial help, and works with the doctor's office and specialty pharmacy
- A benefits check showing whether Hemlibra is covered, whether prior authorization is needed and which specialty pharmacy the plan prefers
- A copay program for commercial insurance, as little as $0 per treatment, up to $15,000 a year, at (844) 436-2672
- No copay help for Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, VA or DoD coverage
- Referrals to independent copay foundations, including for people on Medicare or Medicaid
- Free Hemlibra from the Genentech Patient Foundation for people who qualify, at (888) 941-3331
- A sharps disposal program through 1-866-HEMLIBRA (1-866-436-5427) Supplies and storage
Details as the drugmaker publishes them. Financial assistance
Five questions for the pharmacist or the support line
- Which vials make up my dose, and how many cartons come in each shipment?
- When should I order my maintenance vials, since my dose changes at week 5?
- Which syringe, transfer needle and injection needle come with my order?
- What do I do if the vials were left out of the fridge during delivery?
- Which bleed treatment do I keep at home, and how much aPCC is too much for me?
- How do I get a sharps container and get rid of used needles?
Questions people ask in the first weeks
How long does it take to start Hemlibra after it is prescribed?
There is no fixed number of days for this step. Both the Prescriber Service Form and your Patient Consent Form must reach HEMLIBRA Access Solutions before the benefits check starts. After approval, the specialty pharmacy ships the vials, and the clinic trains you before the first dose.
How often is Hemlibra given?
Once a week for the first 4 weeks as a loading dose. From week 5 the hematologist chooses 1.5mg/kg every week, 3mg/kg every 2 weeks or 6mg/kg every 4 weeks.
Can my child give their own Hemlibra shot?
The label does not recommend self-injection for children under 7, so a caregiver gives those doses. Older children and adults may self-inject after training, if a healthcare provider decides it is appropriate.
Do I keep using factor VIII or bypassing agents on Hemlibra?
The label says prophylactic bypassing agents stop the day before the first dose, and prophylactic factor VIII may continue during the first week. Factor VIII or a bypassing agent can still treat a breakthrough bleed. If aPCC (FEIBA) is needed, talk to your hematologist before going over 100 units per kilogram in total.
Why do my blood clotting tests look different on Hemlibra?
Hemlibra makes aPTT and tests based on it read falsely, including one-stage factor VIII and clotting-based inhibitor tests. The label says chromogenic tests using bovine proteins can be used instead. The effect can last up to 6 months after the last dose, so tell every lab.
What if I miss a dose of Hemlibra?
The label says to give the missed dose as soon as possible, then return to the usual schedule. Do not give 2 doses on the same day to catch up.
Does Medicare cover the Hemlibra copay card?
No, the copay program excludes Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, VA and DoD coverage. Genentech lists independent foundations that may help people on Medicare or Medicaid. The Genentech Patient Foundation may give it free to those who meet its income rules.
Free email alert
Hear when the Hemlibra label changes
One email the day the FDA revises the Hemlibra label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Hemlibra only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Hemophilia A for new trials, FDA decisions and label changes for every treatment.
Sources
- DailyMed - HEMLIBRA- emicizumab injection, solution (prescribing information and Medication Guide, revised July 2025, SPL version 17), Genentech, via DailyMed, July 11, 2025.
- Approved Risk Evaluation and Mitigation Strategies (REMS), FDA, November 7, 2026.
- HEMLIBRA® (emicizumab-kxwh) Dosing Options, Genentech, November 7, 2026.
- HEMLIBRA® (emicizumab-kxwh) Supplies and Storage, Genentech, November 7, 2026.
- Financial Assistance Options | HEMLIBRA® (emicizumab-kxwh), Genentech, November 7, 2026.
- Case Managers | HEMLIBRA® (emicizumab-kxwh), Genentech, November 7, 2026.
- Genentech Pro | HEMLIBRA® (emicizumab-kxwh), Genentech, November 7, 2026.
- Hemophilia – Non-Factor Routine Prophylaxis Products – Hemlibra, Drug Coverage Policy IP0121, Cigna, September 1, 2026.
- BLA 761083/S-020 supplement approval letter, hypersensitivity in postmarketing experience, FDA, July 8, 2025.
- BLA 761083/S-018 supplement approval letter, 12 mg/0.4 mL vial and immunogenicity updates, FDA, January 31, 2024.
- BLA 761083/S-015 supplement approval letter, rash, urticaria and angioedema in postmarketing experience, FDA, June 6, 2022.
- BLA 761083/S-013 supplement approval letter, updated immunogenicity data, FDA, December 16, 2021.
- BLA 761083/S-011 supplement approval letter, hepatic and renal impairment and aPCC interaction up to 6 months, FDA, September 2, 2021.
- BLA 761083/S-002 and S-004 supplement approval letter, hemophilia A with or without inhibitors and 6 mg/kg every 4 weeks, FDA, October 4, 2018.
- BLA 761083 approval letter, HEMLIBRA (emicizumab-kxwh) injection, FDA, November 16, 2017.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing hematologist. Found an error? Use the report link in the footer and it will be checked against the source.